Carissa F. Etienne, director of the Pan American Health Organization (PAHO), announced the launch of the Regional Platform to Advance the Manufacturing of COVID-19 Vaccines and other Health Technologies in the Americas, describing it as an initiative that will “coordinate across sectors—health, science and technology, and industry—to strengthen their capacity to produce new technologies.”
A UN official explained the need for the platform, saying, “limited [global] production and unequal distribution of vaccines in the face of staggering demand hinder our COVID response.”
So far, only about 23% of people in the region have been fully vaccinated, and in many countries, coverage is much lower. The platform will support collaboration across states and agencies, applying existing regional biomanufacturing capacity to produce COVID-19 vaccine shots as well as other medical technologies.
The principle is that manufacture should benefit the entire region, with regional pharmaceutical production and vaccine distribution to all countries by PAHO’s Revolving Fund.
During a recent virtual meeting, Etienne invited public and private manufacturers to submit expressions of interest in producing the materials for an mRNA vaccine, which is highly effective in combating COVID-19.
“Mass vaccination is critical if we are to stem the tide of this pandemic and hinder the spread of further variants,” she said.
Regional supply ingredients
At the meeting, other leaders from international financial institutions, governments, and public health agencies raised numerous aspects of regional medical technologies production.
“Without urgent action to boost the supply of COVID-19 vaccines, the world will not be able to bring the pandemic under control,” pointed out Anabel González, deputy director-general of the World Trade Organization (WTO), highlighting the contribution of regional vaccine production. She added that “regional diversification of production” could play an important role in increasing supply.
Etienne focused on the need to “build the infrastructure and technical capacity to break the cycle of dependency on a highly concentrated global vaccine market” as well as “concrete initiatives” to bring mRNA technology to the region.
“But most of all, we have noted the need for coordination, collaboration, investment, and solidarity,” she said. “We believe [they] will be the essential ingredients for the development and production of new medical technologies in Latin America and the Caribbean.”
An earlier invitation to public and private manufacturers interested in the transfer of mRNA technology into the region has resulted in 30 submitted proposals, which PAHO is reviewing.
Decisions are expected this month.